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Introduction and Hypothesis. We sought to determine the mesh extrusion (vaginal exposure) rates and subject outcomes following
IntePro (Type I polypropylene) mesh “kit” repairs for vaginal prolapse. Methods. Data were pooled from two prospective
multicenter studies evaluating the safety and eﬃcacy of the Perigee and Apogee (American Medical Systems, Minnetonka, Minn,
USA) to treat anterior and posterior/apical prolapses, respectively. Extrusions involving the anterior compartment (AC) or
posteriorcompartment/apex(PC/A)wererecorded.Results.Twohundredsixtywomenunderwentmeshplacement,withatotalof
368mesh units inserted (173 in the AC and 195 in the PC/A). Extrusions were noted in 13 (7.5%) of AC implants and 27 (13.8%)
of PC/A implants through 12 months. No diﬀerence was seen between those with and without extrusion in regard to anatomic
cure, postoperative painor quality of life at 1 year. Conclusions.E x t r u s i o nh a dn oa p p a r e n te ﬀect on short-term outcomes. Given
the unknown long-term sequellae of vaginal mesh exposure, a thorough assessment of risks and beneﬁts of transvaginal mesh
placement should be considered at the time of preoperative planning.
1.Introduction
Pelvic organ prolapse (POP) represents an attenuation or
disruption of the vaginal muscularis comprising the pub-
ocervical “fascia” anteriorly or rectovaginal “fascia” pos-
teriorly, manifesting as anterior or posterior vaginal wall
prolapse, respectively. Additionally, a weak or torn cardinal-
uterosacral ligament complex may lead to apical or uterine
descent. Traditional transvaginal correction of vaginal wall
defects through native tissue repair relies on the use of
compromisedmuscularandconnectivetissueelements.Such
repairs exhibit variable durability as evidenced by an overall
reoperation rate approaching 30% [1]. The prospective
success rates of traditional anterior colporrhaphy range from
30% to 81% at a mean followup of 1 to 2 years [2–6].
Inthecorrectionofposteriorvaginalwallprolapse,tradi-
tional rectovaginal “fascial” plication and site-speciﬁc defect
repairs have yielded retrospective success rates ranging from
76% to 82%, representing variable deﬁnitions of cure with
followup from 6 to 42.5 months [7–9]. In an eﬀort to
enhance anatomic durability, surgeons have employed a
number of biologic grafts or absorbable synthetic mesh to
reinforce a traditional repair or replace disrupted or deﬁcient
vaginalmuscularis.Outcomesfromanumberofrandomized
controlled trials (RCTs) evaluating the eﬃcacy of such
products in both anterior and posterior compartments are
variable [3–6, 10].
The use of nonabsorbable synthetic mesh has been the
most recent evolution in vaginal reconstructive surgery, with
data from the generalsurgeryliterature conﬁrming anatomic
durability following abdominal wall hernia repairs employ-
ing permanent material [11]. Initial prospective data from
Julian and Grody showed signiﬁcant beneﬁt from nonab-
sorbable mesh in the anterior compartment. Subjects re-
ceiving Marlex for reinforcement over plication/paravag-
inal repair had less recurrence than those receiving pli-
cation/paravaginal repair alone, reporting success rates of
100% and 67%, respectively (followup of 2 years) [12].2 Obstetrics and Gynecology International
More recent RCTs on the use of nonabsorbable mesh in the
anterior compartment have also shown signiﬁcantly greater
anatomic durability following the addition of polypropylene
mesh to native tissue plication [4, 13, 14].
Nonabsorbable synthetic mesh in the posterior compart-
ment was evaluated prospectively by Rutmanet al., reporting
a 98% success rate in the treatment of rectocele [15]. In an
RCT by Withagen et al., the use of nonabsorbable synthetic
meshforposteriorrepairresultedinbetteranatomicdurabil-
ity versus native tissue, with 12-month successrates of 95.9%
and 75.5%, respectively, [14].
The most commonly described nonabsorbable synthetic
mesh in both the gynecologic and urologic literature is Type
I polypropylene, which possesses the mechanical properties
of durability, elasticity, and resistance [16] in addition to
the in vivo characteristics of good tissue integration with
minimal inﬂammatory response [17]. Placing polypropylene
mesh in the vagina, however, is associated with an inherent
risk of extrusion on the order of 2.3% to 25% [12, 18–
22] from prospective data for the anterior wall and 2% to
12% [15, 23] for the posterior wall. Mesh “kits” have been
available since 2004, oﬀering the theoretical beneﬁt over free
mesh in enabling placement of synthetic material without
signiﬁcant dissection, reducing operative morbidity allowing
forinsertionwithouttension,andpreservingnormalvisceral
function. Early retrospective data on 77 subjects receiving
Perigee showed an average blood loss of 77 cc with no
postoperative reports of urinary retention [24].
Our objective was to determine the rate of extrusion in
subjects receiving Type I polypropylene mesh in the repair
of pelvic organ prolapse employing Perigee (to treat anterior
vaginal prolapse) and/or Apogee (to treat posterior and/or
apical vaginal prolapse).
2.MaterialsandMethods
2.1. Study Design. Data were collected from two prospective
multicenter clinical studies evaluating the safety and eﬃcacy
of two IntePro (Type I, large pore, polypropylene mesh)
“kits.” The PERIGEE Synthetic Study enrolled subjects
with anterior vaginal prolapse utilizing the Perigee System
(American Medical Systems, Minnetonka, Minn, USA), and
the PROPEL Study (Phase I) enrolled subjects with posterior
vaginal prolapse and/or apical descent for which the Apogee
System was employed. Concomitant repairs of nonstudy
vaginal wall compartments with IntePro were permitted in
each trial allowing for evaluable data on both devices from
either study. Each had similar protocols, inclusion/exclusion
criteria, and data collection such that pooling of data for
purposes of examining mesh complications and outcomes
was deemed appropriate.
All sites received institutional review board approval
prior to enrollment. Each investigator was required to have
performed a minimum of ﬁve Perigee and ﬁve Apogee
implants prior to participation. Subjects were required to
have a diagnosis of prolapse ≥ S t a g eI Ib yt h ep e l v i co r g a n
prolapse quantiﬁcation system (POP-Q) [25] in the com-
partment undergoing correction and were excluded with any
of the following conditions: prior graft-augmented repair;
systemic or local conditions that would preclude surgery
or aﬀect healing such as coagulation disorders, infection,
compromised immune response, vaginal bleeding, erosion,
tissue necrosis, or uncontrolled diabetes mellitus; restricted
leg motion (inability to conform to the lithotomy position).
Data were collected at baseline, procedure, 3 months, 6
months,and12months.Physicalexaminationofthesurgical
site was conducted at each visit and mesh extrusions were
recorded as to compartment, days to onset, intervention for
resolution, and location of vaginal wall exposure (PROPEL
Study only). POP-Q measurements were completed by the
same trained individual at each institution at baseline, 6
months, and 12 months to preserve comparative validity.
Pelvic pain scores (Wong-Baker FACES Pain Rating Scale
ranging from 0 for “no pain” to 10 for “worst pain”)
[26] were recorded at baseline, 6 weeks, and 3 months.
Validated quality of life (QoL) questionnaires including the
Pelvic Floor Distress Inventory (PFDI), Pelvic Floor Impact
Questionnaire—Short Form 7 (PFIQ-7), and Pelvic Organ
Prolapse Urinary Incontinence Sexual Function Question-
naire (PISQ-12) were completed by subjects at baseline and
at 12 months [27–29]. A Patient Satisfaction Survey was also
administered at 6 and 12 months to subjects in the PROPEL
Trial.
2.2. Surgical Procedures. Each subject underwent transvagi-
nal placement of IntePro (mesh density 50 grams/M2)b y
means of bilateral double transobturator trocars for Perigee
and bilateral transgluteal trocars for Apogee. Mesh was
anchored to the pelvic sidewall via self-ﬁxing appendages
( 4f o rP e r i g e ea n d2f o rA p o g e e )a n dc u s t o m i z e dt ot h e
subject’s anatomyandrepair requirementsby means oftrim-
ming. The appendages are constructed of a polypropylene
monoﬁlament that is precut to 1.1cm in width ×23cm in
length and have properties that allow for tissue anchoring
and ingrowth. A single polypropylene tensioning suture is
prethreaded through the length of each appendage to allow
fortensioning afterplacement. Each mesh systemis intended
to remain in the body as a permanent implant and is not
absorbed or degraded by the action of ingrowth or tissue
enzymes.
Preoperatively,patientsreceivedintravenouscephalospo-
rin or quinolone within an hour of surgery. Operative tech-
niques for Perigee and Apogee were as previously described
[24, 30]. In general, a vertical midline incision ≤5c e n t i -
meters in length was employed in both the anterior and
posterior compartments. A full-thickness dissection was
achieved following inﬁltration with local anesthetic for both
hemostasis and dissection of planes. Little or no trimming
of the vaginal muscularis was performed, and closure was
with delayed absorbable suture employing a technique at
the discretion of the surgeon. Additional reconstructive
procedures were performed as indicated with the exception
of concomitant repairs in the same vaginal segment. Vaginal
packing was placed and removed within 12–24 hours.
2.3. Analyses. Patients who received mesh were categorized
into four groups: (1) subjects with mesh in the anterior
compartment who experienced extrusion along the anteriorObstetrics and Gynecology International 3
vaginal wall; (2) subjects with mesh in the anterior compart-
ment who did not experience extrusion; (3) subjects with
mesh in the posterior compartment/apex who experienced
extrusion along the posterior vaginal wall/apex; (4) subjects
with mesh in the posterior compartment/apex who did not
experience extrusion.
Anatomic cure was deﬁned as POP-Q ≤ Stage I for each
vaginal segment. Cure rates were compared between the
extrusion and nonextrusion groups for each compartment.
Within-group and between-group comparisons were carried
out for mean Wong Baker FACES pain scale, PFDI, PFIQ-7,
and PISQ-12 scores.
Continuous data weresummarizedasmean ±SD.Count
and percent were reported for categorical data. Wilcoxon
rank-sum test was used for between group (unpaired) com-
parisons, and the paired t-test or signed rank test was
used for within group (paired) comparisons. Chi-square
or Fisher exact tests were employed to compare categorical
outcomes between groups, and McNemar test was employed
to compare categorical outcomes within groups. Univariate
analysis was used to assess the eﬀect of potential risk factors
for extrusion. A P value <0.05 was considered statistically
signiﬁcant. Data were analyzed using SAS version 9.2 (Cary,
NC, USA).
3. Results
Two hundred sixty women underwent IntePro placement
(173 in the AC and 195 in the PC/A) during participation
in either of the two studies at a total of 19 academic and
community urogynecologic, urologic, or gynecologic prac-
tices in the United States. All subjects have passed beyond
the 12-month post procedure followup time point. Mean
followup was 10.9 ± 3.1a n d1 0 .9 ± 3.0 months for the AC
a n dP C / Ag r o u p s ,r e s p e c t i v e l y ,a ss o m es u b j e c t sw e r el o s tt o
followup prior to one-year. Thirteen of 173 (7.5%) subjects
who had Perigee experienced mesh extrusion along the
anteriorwall.Twenty-sevenof195(13.8%)subjectsreceiving
Apogee experienced mesh extrusion along the posterior or
apical portion of the vagina. One subject who received
Apogee (0.5%) experienced an erosion of IntePro into the
rectum detected 401 days after implant by routine fecal
occult blood testing. This event was successfully treated in
the operating room by transanal trimming of exposed mesh
(3mm) followed by a two-layer closure. Following repair,
the subject maintained anatomic success and experienced no
further sequelae. There were no other erosions of mesh into
the bladder or rectum reported in either study.
Subjects with extrusions exhibited similar baseline char-
acteristics to those without, except for prior hysterectomy
in the AC group. Age, moderate to severe vaginal atrophy
determined by vaginal pH, or history of prior failed repairs
in the same compartment as possible covariates were not
signiﬁcant risk factors for extrusion for either AC or PC/A
mesh placement (Table 1).
Vaginalexposureofmeshoccurredatamedianof95days
and 93 days after surgery for the AC and PC/A, respectively,
(Table 2). Twenty-three percent (3/13) of AC and 48.1%
(13/27) of PC/A extrusions were treated noninvasively
through application of vaginal estrogen cream, antibiotics,
and/or trimming of exposed mesh in an oﬃce setting. All
others were treated by trimming of mesh and repair of the
epithelial defect in the operating room. No extrusion or
erosionrequiredremovaloftheentiremeshsystem;however,
one subject underwent removal of the central portion. Data
on the location of extrusions (midline, apical, or distal)
were available for subjects participating in the PROPEL
S t u d yo n l y( Table 3). Eight subjects (61.5%) with a PC/A
extrusion and two subjects (100%) with an AC extrusion
exhibited a midline exposure. Eight percent (1/13) of those
with extrusion of the PC/A had an apical extrusion.
Baseline and followup anatomic evaluations, periop-
erative pain scores, and QoL analyses are presented in
Table 4. The percentage overall of Perigee (AC) patients with
anatomic cure at 12 months was 84.2% (123/146). The
percentage overall of Apogee (PC/A) subjects with anatomic
cureasmeasuredbyapicalstagingwas92.5%(37/40),andby
posteriorwallstagingwas95.6%(152/159)at12months.No
diﬀerence in anatomic success was seen between extrusion
versus nonextrusion patients.
Meanpainscoreswerenotsigniﬁcantlydiﬀerentbetween
subjects with and without vaginal mesh extrusion in the
AC or PC/A at baseline and at 12 months. QoL analyses
showed similar improvement (from baseline to followup at
12months)inextrusionversusnonextrusionsubjectsineach
compartment. Dyspareunia (subject self-report from PISQ-
12, number 5) in the AC and PC/A groups was neither
signiﬁcantly diﬀerent at 12 months compared to baseline,
nor between groups at 12 months.
Patient satisfaction was recorded in the PROPEL Study
and revealed 96.4% (106/110) to report “some” or “a lot”
of improvement, 94.5% (104/110) who were “moderately,”
“very,” or “extremely” satisﬁed, and 100% who would
“recommend this procedure to a friend suﬀering from
prolapse.”
4. Discussion
Our extrusion rate of 7.5% in the AC is higher than that
reported by Nguyen and Burchette, who identiﬁed 2 of
37 subjects (5%) to exhibit vaginal exposure at 1 year as
part of a randomized controlled study comparing Perigee
with anterior repair to tissue plication alone [13]. Both
subjects were treated conservatively. Moore and Miklos
retrospectively reported a 6.5% extrusion rate in 77 subjects
undergoing Perigee at a mean followup of 18.2 months
[24]. Four extrusions out of 72 subjects receiving Perigee
(5.6%) were reported by Gauruder-Burmester et al., with all
requiring revision in an unknown setting [30]. Two out of
32 subjects (6.3%) receiving Perigee and 3 out of 30 (10%)
implantedwithApogeeexhibitedextrusioninaretrospective
analysis of 70 subjects treated with IntePro, with all cases
unresponsive to conservative therapy [31]. This 10% rate of
posterior vaginal wall extrusion is less than the 13.8% found
in our studies.
Vaginal extrusion in our pooled samples occurred at
a median onset of 95 days (range 34–426) and 93 days
(range 3–418) for the AC and PC/A, respectively. The4 Obstetrics and Gynecology International
Table 1: Subject demographics.
AC mesh, N = 173 PC/A mesh, N = 195
Baseline characteristic Extrusion
N = 13
No extrusion
N = 160 P value Extrusion
N = 27
No extrusion
N = 168 P value
Age∗ 58.6 ± 10.4, 60.8 ±12.8, 0.48W 56.3 ±15.3, 58.7 ±12.2, 0.37W
BMI 25.4 ±3.7, 27.8 ±5.9, 0.21W 28.2 ±7.9, 28.6 ±5.6, 0.42W
Parity 3 ± 2, 3 ±2, 0.53W 3 ±1, 3 ±2, 0.28W
Prior failed prolapse procedure: Cystocele∗ 4 (30.8%) 25 (15.6%) 0.24F ———
Prior failed prolapse procedure: Rectocele∗ — — — 3 (11.1%) 9 (5.4%) 0.22F
Prior failed prolapse procedure: apical∗ — — — 2 (7.4%) 7 (4.2%) 0.36F
Prior hysterectomy∗ 12 (92.3%) 74 (46.3%) 0.00C 13 (48.1%) 84 (50.0%) 0.86C
Postmenopausal 13 (100%) 125 (78.1%) 0.07F 20 (74.1%) 126 (75.0%) 0.92C
Estrogen therapy at baseline 9 (69.2%) 72 (45.0%) 0.09C 15 (55.6%) 87 (51.8%) 0.72C
Diabetic 1 (7.7%) 13 (8.1%) 1.00F 3 (11.1%) 17 (10.1%) 1.00F
Moderate to severe vaginal atrophy at baseline
(based on pH)∗ 3 (23.1%) 39 (24.4%) 1.00F 6 (22.2%) 33 (19.6%) 0.77C
∗Covariates assessed for the risk of an extrusion.
WWilcoxon rank sum test; Cchi-square test; FFisher exact test.
AC: anterior compartment; PC/A: posterior compartment/apex; BMI: body mass index.
Table 2: Extrusion incidence and treatment.
Extrusion AC mesh + extrusion PC/A mesh + extrusion
N 13/173 (7.5%) 27/195 (13.8%)
Days to onset
Mean 155 123
Median 95 93
Min 34 3
Max 426 418
Mesh trimmed in
OR 10/13 (76.9%) 14/27 (51.9%)
Noninvasive
Treatment∗ 3/13 (23.1%) 13/27 (48.1%)
∗Noninvasive treatment consisted of application of vaginal estrogen cream,
antibiotics, and/or trimming of exposed mesh in the oﬃce.
AC: anterior compartment; PC/A: posterior compartment/apex.
Table 3: Extrusion location (PROPEL Study).
Location of
extrusion
AC Mesh + extrusion
N = 2/59
PC/A Mesh + extrusion
N = 13/141
Midline 2/2 (100%) 8/13 (61.5%)
Apical — 1/13 (7.7%)
Distal — 4/13 (30.8%)
AC: anterior compartment; PC/A: posterior compartment/apex.
cases of delayed exposure are consistent with data from
Boulanger et al., who reported a mean interval of 26.6
months between vaginal mesh implant and removal in 16
patients (of whom 62% exhibited symptomatic extrusion)
[17]. In an eﬀort to determine etiology, bacterial analysis
of each of the 16 explants was performed, with culture
most commonly identifying Streptococcus species. As none
of the colony counts were found to exceed 104, the role of
bacterialcontaminationinregardtomeshcomplicationswas
deemedunclearbytheauthors.Similardatawerereportedby
Petros et al. in an early retropubic sling feasibility study, who
identiﬁed bacterial concentrations of <105 in 8 explanted
synthetic tapes having been placed with free vaginal ends in
a canine model for up to 19 weeks [32].
No correlations were identiﬁed in our study between
age, baseline vaginal pH, or history of prior failed repairs in
the same compartment. The absence of a correlation with
age diﬀers from ﬁndings by Deﬃeux et al. who reported
an increased risk of polypropylene mesh extrusion with
increased age (>70 years) [33]. Our choice of vaginal pH
as an indicator of local estrogenization (presence of vaginal
atrophy) was chosen as a covariate, as hormone replacement
therapy may vary in terms of route of delivery, dose pre-
scribed, length of administration, and subject compliance.
In our studies, the lack of correlation between estrogen
status (moderate to severe vaginal atrophy) at baseline and
extrusion rate is consistent with a previously unpublished
study [34]. Moore et al. prospectively examined 98 women
receiving Perigee with IntePro with baseline vaginal mucosal
maturation cytological indices. Six (6.1%) subjects exhibited
vaginal extrusion of mesh of which only 1 had a low estrogen
eﬀect (severe vaginal atrophy) and the rest an adequately
estrogenized vaginal epithelium.
The ﬁnding of prior hysterectomy as a risk factor for
extrusion in subjects treated with Perigee is surprising, given
that no such correlation was found between PC/A mesh
placement employing Apogee in which contact between
polypropylene and the apical scar may have been more
common. Unpublished data has been presented on a sub-
group of patients from the PROPEL Study in which a
similar apical extrusion rate was found in those with (2.8%)
and without (1.0%) hysterectomy at the time of Apogee
with IntePro placement in the PC/A [35]. As reported by
Collinet et al., hysterectomy with an inverted “T” colpotomyObstetrics and Gynecology International 5
Table 4: Outcome variables for subjects with and without extrusion (AC or PC/A).
Variable1 Baseline
extrusion
Baseline
nonextrusion
12-Month
extrusion
12-Month
nonextrusion
P value
(within group)2
P value
(between
groups)3
Anterior compartment
POPQ 13/13 160/160 1/12 22/134 NA NA
Anterior stage ≥ II (100.0%) (100.0%) (8.3%) (16.4%) NA 0.692
Wong-Baker 1.8 ±2.81 .6 ±2.01 .3 ±2.40 .5 ±1.1 0.781 0.685
Pain score4 (n = 13) (n = 160) (n = 13) (n = 151) <.001 0.228
PFDI (symptoms) 44.6 ±24.63 5 .7 ±26.21 6 .7 ±20.41 4 .4 ±20.4 0.024 0.243
Anterior POPDI (n = 13) (n = 160) (n = 12) (n = 135) <.001 0.715
PFDI (symptoms) 130.2 ±58.2 101.4 ±55.64 0 .0 ±43.33 2 .3 ±39.4 <.001 0.075
UDI (n = 13) (n = 160) (n = 12) (n = 135) <.001 0.523
PFIQ-7 (life impact) 31.1 ±37.01 6 .6 ±24.01 2 .7 ±26.93 .6 ±12.4 0.008 0.186
POPIQ (n = 13) (n = 159) (n = 12) (n = 134) <.001 0.267
PFIQ-7 (life impact) 42.9 ±33.43 2 .8 ±27.41 9 .8 ±26.68 .1 ±15.9 0.061 0.211
UIQ (n = 13) (n = 160) (n = 12) (n = 134) <.001 0.158
PISQ-12 31.1 ±7.73 2 .0 ±7.13 4 .1 ±8.73 7 .5 ±5.9 0.151 0.693
(If sexually active) (n = 10) (n = 84) (n = 8) (n = 67) <.001 0.149
Dyspareunia 5/10 36/83 5/82 0 /67 1.000 0.745
(From PISQ-12, number 5) (50.0%) (43.4%) (62.5%) (29.9%) 0.491 0.108
Posterior compartment/Apex
POPQ 5/27 42/168 1/23 4/141 0.180 0.629
Apical stage ≥ II (18.5%) (25.0%) (4.3%) (2.8%) <.001 0.535
POPQ 27/27 163/168 0/23 7/141 NA 1.000
Posterior stage ≥ II (100.0%) (97.0%) (0.0%) (5.0%) <.001 0.595
Wong-Baker 1.1 ±1.92 .0 ±2.50 .7 ±0.90 .5 ±1.0 0.367 0.094
Pain score4 (n = 27) (n = 167) (n = 26) (n = 162) <.001 0.409
PFDI (symptoms) 48.5 ±38.34 7 .2 ±36.02 7 .2 ±35.41 9 .5 ±27.9 0.001 0.863
POPDI posterior (n = 27) (n = 167) (n = 23) (n = 141) <.001 0.242
PFDI (symptoms) 133.2 ±89.6 127.7 ±85.56 8 .4 ±79.55 0 .2 ±60.6 <.001 0.759
CRADI (n = 27) (n = 167) (n = 23) (n = 141) <.001 0.204
PFIQ-7 (life impact) 21.7 ±27.51 9 .1 ±25.82 .9 ±8.54 .6 ±14.2 <.001 0.637
POPIQ (n = 27) (n = 165) (n = 23) (n = 140) <.001 0.432
PFIQ-7 (life impact) 18.3 ±26.62 2 .9 ±27.21 0 .1 ±18.34 .8 ±13.9 0.093 0.415
CRAIQ (n = 27) (n = 165) (n = 23) (n = 140) <.001 0.105
PISQ-12 33.4 ±6.43 2 .3 ±7.43 8 .6 ±4.93 6 .9 ±6.2 0.046 0.592
(If sexually active) (n = 15) (n = 104) (n = 15) (n = 83) <.001 0.323
Dyspareunia 7/15 43/105 3/15 28/83 0.083 0.782
(From PISQ-12, number 5) (46.7%) (41.0%) (20.0%) (33.7%) 0.450 0.376
1Values are presented as N (%) or Mean ± SD; NA: Not Available.
2P value paired comparison between baseline and 12 Months for the extrusion group and nonextrusion group.
3P value unpaired comparison between extrusion group and nonextrusion group for the baseline time-point and the 12-month time-point.
4Data at 3-month followup (Wong-Baker FACES pain scores were not collected at 12-month).
was an independent risk factor for extrusion in a sample of
subjects receiving a Prolene transvaginal mesh [36].
In the PROPEL Study, we examined speciﬁc sites of mesh
extrusion to determine where along the vaginal wall subjects
were most prone to exposure, determining that the majority
of exposures occurred along the midline. This ﬁnding may
be consistent with wound separation associated with mesh
contracture and/or hematoma [37].
Extrusions were treated conservatively (vaginal estrogen
cream,antibiotics,and/ortrimmingintheoﬃce)inapproxi-
mately25–50%ofcases,andthosereturningtotheoperating
room (5.8% for Apogee and 7.2% for Perigee overall) for6 Obstetrics and Gynecology International
excision were treated by mesh trimming and closure of the
wound without major revision or complete system explant.
An additional, yet unproven, risk factor for vaginal ex-
posure of mesh may be that of material density, as the
lighterweightmesh(25.5grams/M2)comprisingthesecond-
generation elevate has yielded lower extrusion rates com-
pared to those seen in our studies. In unpublished prospec-
tive data, anterior elevate (American Medical Systems, Min-
netonka, Minn, USA) was found to exhibit a mesh exposure
rate of 5.6% at 1 year, while posterior elevate (American
Medical Systems, Minnetonka, Minn, USA) exhibited rates
of 6.5% and 7.9% at 1 and 2 years, respectively, [38–40].
A single case of erosion into the rectum was reported in
ourstudies,representing1/369or0.3%ofmeshunitsplaced.
Such events also remain rare in the literature. Abdel-Fattah
and Ramsay reported one erosion into the bladder following
an anterior Gynecare mesh out of a 146 subjects receiving
polypropylene in the AC (representing an incidence of 0.7%)
with no erosions reported in 149 subjects implanted in the
PC [31].
Anatomic success was high at one year for all patients
in our analysis with no diﬀerence in anatomic durability in
those with and without extrusion. In a study by Bellon et
al., polypropylene showed no diﬀerence in tensile strength
compared with controls upon inoculation with Staphylococ-
cusepidermidisorStaphylococcusaureus30daysafterimplant
into the abdominal wall of a rabbit model [41].
Mean postoperative pain scores were similar in both
groups, and QoL showed similar improvements from base-
line to followup for extrusion versus nonextrusion subjects
in each compartment. Patient satisfaction overall as recorded
for PROPEL subjects was high.
The strength of this study is the prospective enrollment
a n dc o l l e c t i o no fd a t af r o mal a r g en u m b e ro fs u b j e c t sw i t h
a minimum followup of 12 months. Validated instruments
for measurement of anatomic success, and QoL provided
uniformityindatainterpretation.Presentationofdataonthe
incidence of extrusion in the context of anatomic durability
and outcomes allows for a measure of conﬁdence in risk-
beneﬁt evaluations in regard to the use of mesh “kits.”
Study limitations include the large number of surgeons
involved in device implantation, perhaps representing a
range of techniques in regard to wound closure, especially,
with the potential for variations in this regard as a contrib-
utor to the incidence and site of extrusion in some subjects.
Since Perigee and Apogee used in this trial were among the
ﬁrst kits available on the market, enrollment early in the
product life cycle versus later enrollment may aﬀect success
and complication rates as opposed to rates seen today in
the clinical setting. Patients enrolled in the PROPEL Study
represented a sample implanted at a time more remote
from Apogee market introduction, and in unpublished data,
exhibited an extrusion rate of 8.4% at a mean of 11 months
[42]. This lower incidence of vaginal exposure as compared
to the number generated from our pooled data from two
sequential studies reasonably represents a “learning curve.”
Aswewerewithoutapredeterminedsamplesize,theabsence
of a signiﬁcant diﬀerence in observed outcomes (anatomic
durability, postoperative pain, and QoL) between those with
and without extrusion may represent and underpowered
scenario.
Based on our ﬁnding of a preponderance of midline
extrusions, it would be reasonable to suggest a thick dissec-
tion with minimal to no trimming of the vagina, in addition
to a meticulous closure. Additionally, presumptive measures
to reduce bacterial colonization such as appropriate periop-
erativeantibiotics,thoroughperinealpreparation,drapingof
the anal verge, and generous intraoperative irrigation would
be appropriate. Excellent hemostasis to reduce hematoma
formation with vaginal packing could also be beneﬁcial.
Frequent and prolonged followup would be prudent to
allow for extrusion detection and intervention prior to the
progression of mesh exposure to a point that may require
extensive revision.
5. Conclusion
Vaginal extrusion of mesh appears to have no impact on
anatomic durability, postoperative pain or QoL at 1 year.
Given the unknown long-term sequellae of vaginal mesh
exposure, a thorough assessment of risks and beneﬁts of
transvaginal mesh placement should be thoughtfully consid-
ered.
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